Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated (DGX) provides essential diagnostic insights and testing services across the U.S. healthcare system. This news hub aggregates official press releases, financial updates, and strategic developments from one of America's leading clinical laboratory networks.
Investors and healthcare professionals will find timely updates on earnings reports, partnership announcements, and technological advancements in diagnostic testing. Our curated news feed includes regulatory milestones, service expansions, and innovations leveraging DGX's vast clinical database.
Key updates cover emerging trends in precision diagnostics, laboratory network growth, and healthcare collaborations. Users can track the company's progress in cancer detection, genomic testing, and data-driven health solutions through verified primary sources.
Bookmark this page for direct access to DGX's latest financial performance data, leadership changes, and operational developments. Visit regularly to stay informed about how Quest Diagnostics continues shaping diagnostic medicine through clinical excellence and strategic initiatives.
Quest Diagnostics (DGX) reported strong Q4 2024 financial results with revenues of $2.62 billion, up 14.5% year-over-year, and full-year revenues of $9.87 billion, up 6.7%. Q4 reported diluted EPS reached $1.95, increasing 14.7%, while adjusted diluted EPS was $2.23, up 3.7%.
The company completed eight acquisitions in 2024, including LifeLabs in Canada, expanded its health plan access to over 90% of in-network lives nationwide, and grew its Advanced Diagnostics portfolio. For 2025, Quest expects revenues between $10.70-10.85 billion and adjusted diluted EPS of $9.55-9.80.
The Board authorized a 6.7% increase in quarterly dividend to $0.80 per share, marking continuous dividend growth since 2011.
Quest Diagnostics (NYSE: DGX) has completed its previously announced acquisition of select assets from University Hospitals, a leading nonprofit health system and academic medical center. The acquisition expands Quest's presence in Ohio, providing broader access to its diagnostic testing services, patient access sites, and health plan coverage network.
Testing for University Hospitals' providers and patients using Quest's services will be performed at Quest's laboratories in Twinsburg, Ohio and Pittsburgh, Pennsylvania. University Hospitals will maintain operation of its hospital-based labs for inpatient and select outpatient testing. Financial terms of the acquisition were not disclosed.
Quest Diagnostics (NYSE: DGX) has appointed Adrienne L. Brott as senior vice president and chief quality and regulatory affairs officer, effective December 2024. Reporting to CEO Jim Davis, Brott will lead the company's quality and regulatory strategy, focusing on enhancing quality adherence and compliance with global regulations for laboratory diagnostic services.
Brott joins Quest with extensive experience in healthcare quality and regulatory affairs, previously serving as senior vice president of quality and regulatory at Getinge's acute care therapies division. Her prior roles include leadership positions at Becton Dickinson, where she managed quality across 28 manufacturing sites and led a program to harmonize 120 quality management systems. She also held positions at Johnson & Johnson and Abbott Laboratories.
The new executive is co-chair of the Advancing Quality Excellence Collaborative Community Steering Committee of the Medical Device Innovation Consortium, collaborating with stakeholders including the FDA to improve medical device quality and patient safety.
Quest Diagnostics highlighted the humanitarian efforts of Kris Constantino, Director of Logistics Operations, in response to Hurricane Helene in North Carolina. Constantino aided county leaders with supply logistics, particularly in Pensacola, which was isolated and dependent on National Guard air drops. She coordinated with the Product Remanufacturing Center (PRC), an Amazon partner, to secure warehouse space for consolidating donations from Yancey County. Constantino established a logistics network with three strategic storefronts to distribute essential supplies including generators, fuel, warm weather gear, and medical supplies. This recognition is part of Quest's Everyday Heroes Program, which acknowledges employees promoting inclusion, diversity, justice, and equity.
Quest Diagnostics (NYSE: DGX) has scheduled the release of its fourth quarter and full year 2024 financial results for Thursday, January 30, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time to discuss the results.
Participants can join the call by dialing 888-455-0391 (U.S. and Canada) or 773-756-0467 (international) using passcode '7895081'. The earnings release and webcast will be available on Quest's investor website. A replay will be accessible until February 13, 2025, via phone or the company's investor website.
Quest Diagnostics has released details about its corporate governance and ethics framework in its 2023 Corporate Responsibility Report. The company, with over 56 years of experience and 70 billion data points, maintains strong oversight through its Board of Directors and Executive Leadership team.
Key highlights include:
- Board composition featuring 50% women and/or diverse race/ethnicity representation, with 9 independent members
- Six specialized board committees overseeing various aspects of operations
- 2023 achievements including $343 million spent with small and diverse US businesses
- Over 95% employee completion rate for compliance training
The company has set ambitious 2025/2026 goals, including expanding ESG risk assessments of key suppliers and growing spend with small and diverse suppliers to $500 million. Quest's ESG Council meets quarterly to drive integration of ESG initiatives, while the Enterprise Risk Management program promotes risk awareness throughout operations.
Quest Diagnostics made significant environmental progress in 2023 through multiple sustainability initiatives. The company purchased over 40 million kilowatt hours of renewable electricity and installed electric vehicle charging stations in Marlborough, Tampa, and Atlanta. Their fleet optimization reduced driving by 2.6 million miles, saving 96,000 gallons of gasoline and 845 metric tons of CO2 emissions.
The company implemented waste reduction programs at major California laboratories, diverting over 3,500 tons of medical and municipal waste from landfills, generating 1 million kilowatt-hours of electricity, and avoiding 6,900 tons of CO2-equivalent emissions. Their box optimization project achieved an 11% reduction in shipping boxes, saving 23 tons of cardboard.
Quest also obtained ISO 14001 certifications for facilities in Cleveland HeartLab and Chantilly, joining their San Juan Capistrano lab. The company established an Environmental Health Impact Committee to address climate change's health impacts and inform related policies.
Quest Diagnostics has detailed its comprehensive approach to protecting patient data privacy and cybersecurity. The company maintains a robust privacy program with detailed policies, procedures, and annual HIPAA training for all employees. Their cybersecurity framework, overseen by the Chief Information Security Officer, includes multiple security measures aligned with industry best practices.
The company's cybersecurity program encompasses various domains including IT risk management, access controls, data protection, threat intelligence, and incident response. Quest has established an IT Risk Council for oversight and prioritizes supply chain security by assessing vendor security postures. The program adheres to multiple security frameworks including NIST 800, MITRE 40 ATT&CK, and ISO standards, with oversight from the Board of Directors through specialized committees.
Quest Diagnostics (NYSE: DGX) announced that Chairman, CEO and President Jim Davis will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference in Miami. The presentation, scheduled for December 4, 2024, at 3:00 p.m. Eastern Time, will cover the company's strategy, performance, and current market trends.
The session will be webcast live and accessible through Quest's investor relations page at ir.QuestDiagnostics.com. An archived version will be available within 24 hours after the event and remain accessible until January 3, 2025.
Quest Diagnostics (NYSE: DGX) has launched a new Health Coaching service on questhealth.com through Pack Health®. The service connects individuals with board-certified health advisers for personalized support in areas including general health, weight management, chronic kidney disease, type 2 diabetes, and high cholesterol. The program offers two packages: a 4-session package for $225 and a 6-session package for $275, including one-on-one virtual coaching sessions, regular communication, a welcome kit, and digital content. Customers can integrate their Quest lab results with coaching for a more tailored experience.
